


PRODUCT INFORMATION



Oclacitinib-¹³C-d₃

Item No. 28808

CAS Registry No.: 2750534-84-8
Formal Name: *trans*-N-methyl-4-(methyl-¹³C-d₃-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
MF: C₁₄[¹³C]H₂₀D₃N₅O₂S
FW: 341.5
Chemical Purity: ≥95% (Oclacitinib)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₃); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oclacitinib-¹³C-d₃ is intended for use as an internal standard for the quantification of oclacitinib (Item No. 18722) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Oclacitinib-¹³C-d₃ is supplied as a solid. A stock solution may be made by dissolving the oclacitinib-¹³C-d₃ in the solvent of choice, which should be purged with an inert gas. Oclacitinib-¹³C-d₃ is soluble in organic solvents such as methanol and DMSO.

Description

Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC₅₀s = 10, 18, 99, and 84 nM, respectively).¹ It is selective for JAK kinases over a panel of 38 additional kinases at 1 μM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-α levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.² Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.

References

- Gonzales, A.J., Bowman, J.W., Fici, G.J., *et al.* Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. *J. Vet. Pharmacol. Ther.* **37**(4), 317-324 (2014).
- Fukuyama, T., Ehling, S., Cook, E., *et al.* Topically administered Janus-kinase inhibitors of oclacitinib and olacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. *J. Pharmacol. Exp. Ther.* **354**(3), 394-405 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/08/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM